1. Search Result
Search Result
Results for "

human adenosine kinase

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

4

Recombinant Proteins

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-19259

    Adenosine Kinase Neurological Disease
    GP3269 is a selective and orally active human adenosine kinase (AK) inhibitor with an IC50 of 11 nM against human adenosine kinase. GP3269 increases adenosine levels at epileptic foci, activates A1 receptors on excitatory neurons, and exhibits anticonvulsant activity in rats. GP3269 does not induce hemodynamic effects including changes in blood pressure or heart rate in rats. GP3269 can be used for epilepsy-related research .
    GP3269
  • HY-179690

    Parasite Adenosine Kinase Infection
    Antiparasitic agent-30 is a potent adenosine kinase TbrAK modulator and antitrypanosomal agent. Antiparasitic agent-30 exhibits significant inhibitory activity against Trypanosoma brucei rhodesiense, while enhancing the activity of recombinant TbrAK(EC50=38 nM, Ka=75 nM-497 nM). Antiparasitic agent-30 exerts its pharmacological effects by eliminating intrinsic substrate inhibition and hyperactivating TbrAK in Trypanosoma brucei rhodesiense. Antiparasitic agent-30 serves as a valuable tool molecule for studying acute African human trypanosomiasis (sleeping sickness) .
    Antiparasitic agent-30
  • HY-E70648

    AMPK Cancer
    AMPK is an αβγ heterotrimeric serinethreonine kinase activated by decreasing concentrations of adenosine triphosphate (ATP) and increasing AMP concentrations. AMPK alpha 1 Recombinant Human Active Protein Kinase is obtained by co-expressing AMPKα1 proteins .
    AMPK alpha 1 Recombinant Human Active Protein Kinase
  • HY-E70793

    AMPK Cancer
    AMPK is an αβγ heterotrimeric serinethreonine kinase activated by decreasing concentrations of adenosine triphosphate (ATP) and increasing AMP concentrations. Biotin-AMPKα1β1γ1 Recombinant Human Active Protein Kinase is obtained by co-expressing AMPKα1, AMPKβ1, and AMPKγ1 proteins and is biotinylated .
    Biotin-AMPKα1β1γ1 Recombinant Human Active Protein Kinase
  • HY-E70787

    AMPK Cancer
    AMPK is an αβγ heterotrimeric serinethreonine kinase activated by decreasing concentrations of adenosine triphosphate (ATP) and increasing AMP concentrations. AMPK α1β1γ1 Recombinant Human Active Protein Kinase is an ortholog of AMPK. AMPK α1β1γ1 Recombinant Human Active Protein Kinase is obtained by co-expressing AMPKα1, AMPKβ1, and AMPKγ1 proteins .
    AMPK α1β1γ1 Recombinant Human Active Protein Kinase
  • HY-110124

    Pyruvate Kinase Cancer
    ML202 is a highly specific allosteric activator of human pyruvate kinase M2 (hPK-M2), which can affect the cooperativity of phosphoenolpyruvate (PEP) binding, while adenosine diphosphate (ADP) binding almost no effect .
    ML202
  • HY-E70796

    AMPK Cancer
    AMPK is an αβγ heterotrimeric serinethreonine kinase activated by decreasing concentrations of adenosine triphosphate (ATP) and increasing AMP concentrations. Biotin-AMPKα2β1γ1 Recombinant Human Active Protein Kinase is obtained by co-expressing AMPKα2, AMPKβ1, and AMPKγ1 proteins and is biotinylated .
    Biotin-AMPKα2β1γ1 Recombinant Human Active Protein Kinase
  • HY-E70795

    AMPK Cancer
    AMPK is an αβγ heterotrimeric serinethreonine kinase activated by decreasing concentrations of adenosine triphosphate (ATP) and increasing AMP concentrations. Biotin-AMPKα1β2γ1 Recombinant Human Active Protein Kinase is obtained by co-expressing AMPKα1, AMPKβ2, and AMPKγ1 proteins and is biotinylated .
    Biotin-AMPKα1β2γ1 Recombinant Human Active Protein Kinase
  • HY-115862

    Adenosine Receptor PARP Aurora Kinase Cardiovascular Disease Cancer
    Benzo[c][1,8]naphthyridin-6(5H)-one exhibits low micromolar affinity to human adenosine receptor (AR) A1 and hA2A, with Ki of 4.6 and 4.8 μM. Benzo[c][1,8]naphthyridin-6(5H)-one is inhibitor for poly ADP-ribose polymerase-1 (PARP-1) and aurora kinase A, with IC50 of 0.311 and 5.5 μM .
    Benzo[c][1,8]naphthyridin-6(5H)-one
  • HY-182503

    Adenosine Kinase Others Inflammation/Immunology
    GP515 is a potent and selective adenosine kinase inhibitor with a human IC50 of 4 nM. GP515 exerts tissue protective effects, produces long-lasting hepatic microcirculation effects after hemorrhagic shock, and induces dose- and time-related VEGF mRNA and protein expression in normoxic rat myocardial myoblasts, with additive VEGF increases during mild hypoxia and no effect during severe hypoxia. GP515 suppresses IFNγ synthesis and CD69 expression in DSS-induced colitis. GP515 also shows a dose-dependent suppression of TNF-α production with an IC50 of 80 μM and can be reversed in the presence of the cAMP antagonist (Rp)-cAMPS. Combinations of GP515 with either adenosine or rolipram led to an additive inhibition of TNF-α synthesis. GP515 can be used for the research of hemorrhagic shock .
    GP515
  • HY-E70794

    AMPK Cancer
    AMPK is an αβγ heterotrimeric serinethreonine kinase activated by decreasing concentrations of adenosine triphosphate (ATP) and increasing AMP concentrations. Biotin-AMPKα1β1γ2 Recombinant Human Active Protein Kinase is obtained by co-expressing AMPKα1, AMPKβ1, and AMPKγ2 proteins and is biotinylated .
    Biotin-AMPKα1β1γ2 Recombinant Human Active Protein Kinase
  • HY-113822

    RS-82856 hydrogensulfate

    Phosphodiesterase (PDE) Cardiovascular Disease Endocrinology
    Lixazinone (RS-82856) hydrogensulfate is a selective inhibitor of cGMP-inhibited phosphodiesterase (PDE3) with an IC50 value of 22 nM. Lixazinone hydrogensulfate exhibits positive inotropic effects, afterload reduction and antithrombotic properties. Lixazinone hydrogensulfate increases cyclic adenosine monophosphate (cAMP) levels in human platelets, inhibits thrombin-induced aggregation of human platelets, and blocks the photolabeling of PDE3 active sites by [ 32P]cGMP. Lixazinone hydrogensulfate can be used in the research of polycystic kidney disease and congestive heart failure .
    Lixazinone hydrogensulfate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: